<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRIMSOL- trimethoprim hydrochloride solution </strong><br>FSC Laboratories, Inc<br></p></div>
<h1>Primsol<span class="Sup">®</span> Solution<br>(trimethoprim hydrochloride oral solution)<br>Dye-free, alcohol-free, flavored solution,<br>50 mg trimethoprim per 5 mL</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PRIMSOL (trimethoprim hydrochloride oral solution) is a solution of the synthetic antibacterial trimethoprim in water prepared with the aid of hydrochloric acid. Each 5 mL for oral administration contains trimethoprim hydrochloride equivalent to 50 mg trimethoprim and the inactive ingredients bubble gum flavor, fructose, glycerin, methylparaben, monoammonium glycyrrhizinate, povidone, propylparaben, propylene glycol, saccharin sodium, sodium benzoate, sorbitol, water and hydrochloric acid and/or sodium hydroxide to adjust pH to a range of 3.0 - 5.0. Trimethoprim is 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine. Trimethoprim is a white to cream-colored, odorless, bitter compound with a molecular formula of C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">3</span> and a molecular weight of 290.32 and the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a06ea7d8-a884-4b62-a87f-c36d824f2aa4&amp;name=primsol-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Trimethoprim is rapidly absorbed following oral administration. It exists in the blood as unbound, protein-bound and metabolized forms. Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3'- and 4'-hydroxy derivatives. The free form is considered to be the therapeutically active form. Approximately 44% of trimethoprim is bound to plasma proteins.</p>
<p>Mean peak plasma concentrations of approximately 1 mcg/mL occur 1 to 4 hours after oral administration of a single 100 mg dose. A single 200 mg dose will result in plasma concentrations approximately twice as high. The mean half-life of trimethoprim is approximately 9 hours. However, patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-life of trimethoprim, which requires either dosage regimen adjustment or not using the drug in such patients (see<a href="#DA"> DOSAGE AND ADMINISTRATION </a>section). During a 13-week study of trimethoprim tablets administered at a dosage of 50 mg <span class="Italics">q.i.d.</span>, the mean minimum steady-state concentration of the drug was 1.1 mcg/mL. Steady-state concentrations were achieved within two to three days of chronic administration and were maintained throughout the experimental period.</p>
<p>Excretion of trimethoprim is primarily by the kidneys through glomerular filtration and tubular secretion. Urine concentrations of trimethoprim are considerably higher than are the concentrations in the blood. After a single oral dose of 100 mg, urine concentrations of trimethoprim ranged from 30 to 160 mcg/mL during the 0- to 4-hour period and declined to approximately 18 to 91 mcg/mL during the 8- to 24-hour period. A 200 mg single oral dose will result in trimethoprim urine concentrations approximately twice as high. After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim.</p>
<p>Trimethoprim half-life, clearance, and volume of distribution vary with age. Excluding newborns, an apparent trend of increasing half-life, volume of distribution, and decreasing clearance is observed with increasing age until adulthood.</p>
<p>Since normal vaginal and fecal flora are the source of most pathogens causing <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, it is relevant to consider the distribution of trimethoprim into these sites. Concentrations of trimethoprim in vaginal secretions are consistently greater than those found simultaneously in the serum, being typically 1.6 times the concentrations of simultaneously obtained serum samples. Sufficient trimethoprim is excreted in the feces to markedly reduce or eliminate trimethoprim-susceptible organisms from the fecal flora. The dominant non-<span class="Italics">Enterobacteriaceae </span>fecal organisms,<span class="Italics"> Bacteroides </span>spp. and<span class="Italics"> Lactobacillus </span>spp., are not susceptible to trimethoprim concentrations obtained with the recommended dosage.</p>
<p>Trimethoprim also concentrates into middle ear fluid (MEF) very efficiently. In a study in children aged 1 to 12 years, administration of a single 4 mg/kg dose resulted in a mean peak MEF concentration of 2.0 mcg/mL.</p>
<p>Trimethoprim also passes the placental barrier and is excreted in breast milk.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-2.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. This binding is very much stronger for the bacterial enzyme than for the corresponding mammalian enzyme. Thus, trimethoprim selectively interferes with bacterial biosynthesis of nucleic acids and proteins.</p>
<p>Trimethoprim has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both<span class="Italics"> in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section.</p>
<p><span class="Bold">Aerobic gram-positive microorganisms</span></p>
<table class="Noautorules" width="60%">
<col align="left" valign="top" width="47%">
<col align="left" valign="top" width="53%">
<tbody class="Headless">
<tr>
<td align="left">
<span class="Italics">Staphylococcus </span>species</td>
<td align="left">(coagulase-negative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, including<span class="Italics"> S. saprophyticus</span>)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td align="left">(penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Aerobic gram-negative microorganisms</span></p>
<table class="Noautorules" width="60%">
<col align="left" valign="top" width="47%">
<col align="left" valign="top" width="53%">
<tbody class="Headless">
<tr>
<td align="left">
<span class="Italics">Enterobacter </span>species</td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td align="left">(excluding beta-lactamase negative, ampicillin resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</td>
</tr>
<tr>
<td align="left"><span class="Italics">Klebsiella pneumoniae</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Proteus mirabilis</span></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>NOTE:<span class="Italics"> Moraxella catarrhalis </span>isolates were found consistently resistant to trimethoprim.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Susceptibility Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<h3>Dilution techniques</h3>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MIC's). These MIC's provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC's should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trimethoprim powder. The MIC values should be interpreted according to the following criteria:</p>
<p>For testing aerobic microorganisms isolated from <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>:</p>
<table width="60%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">MIC (mcg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 8</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr class="Last">
<td align="center">≥ 16</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>When testing<span class="Italics"> Haemophilus influenzae </span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<table width="60%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">MIC (mcg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 0.5</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">1-2</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≥ 4</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>When testing<span class="Italics"> Streptococcus pneumoniae </span><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<table width="60%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">MIC (mcg/mL)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≤ 2</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr class="Last">
<td align="center">≥ 4</td>
<td align="center">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprim<a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a> powder should provide the following MIC values:</p>
<table width="75%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left">Microorganism</th>
<th align="center"></th>
<th align="center">MIC (mcg/mL)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Range applicable only to tests performed by broth microdilution method using<span class="Italics"> Haemophilus </span>Test Medium (HTM).<span class="Sup">1</span>
</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Range applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.<span class="Sup">1</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="center">ATCC 25922</td>
<td align="center">0.5 - 2</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td align="center">ATCC 49247</td>
<td align="center">0.06 - 0.5</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">ATCC 29213</td>
<td align="center">1 - 4</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Streptococcus pneumoniae</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td align="center">ATCC 49619</td>
<td align="center">1 - 4</td>
</tr>
</tbody>
</table>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Interpretive criteria applicable only to tests performed by broth microdilution method using<span class="Italics"> Haemophilus </span>Test Medium (HTM).<span class="Sup">1</span>
</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Interpretive criteria applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.<span class="Sup">1</span>
</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>Trimethoprim very medium-dependent.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<h3>Diffusion techniques</h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg trimethoprim to test the susceptibility of microorganisms to trimethoprim.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg trimethoprim<a name="footnote-reference-6" href="#footnote-6" class="Sup">4</a> disk should be interpreted according to the following criteria:</p>
<p>For testing aerobic microorganisms isolated from <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>:</p>
<table width="60%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">Zone diameter (mm)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥16</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">11-15</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤10</td>
<td align="center"> Resistant (R)</td>
</tr>
</tbody>
</table>
<p>For testing<span class="Italics"> Haemophilus influenzae </span><a name="footnote-reference-7" href="#footnote-7" class="Sup">5</a>:</p>
<table width="60%">
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th align="center">Zone diameter (mm)</th>
<th align="center">Interpretation</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">≥16</td>
<td align="center">Susceptible (S)</td>
</tr>
<tr>
<td align="center">11-15</td>
<td align="center">Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center">≤10</td>
<td align="center"> Resistant (R)</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Note</span>:</p>
<p>Diffusion techniques are not recommended for determining susceptibility of<span class="Italics"> Streptococcus pneumoniae </span>to trimethoprim.</p>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for trimethoprim.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 5 mcg trimethoprim<a href="#footnote-6" class="Sup">4</a> disk should provide the following zone diameters in this laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>:</p>
<table width="75%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left">Microorganism</th>
<th align="center"></th>
<th align="center">Zone Diameter (mm)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Range applicable only to tests performed by disk diffusion method using<span class="Italics"> Haemophilus </span>Test Medium (HTM).<span class="Sup">2</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics">Escherichia coli</span></td>
<td align="center">ATCC 25922</td>
<td align="center">21 - 28</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</td>
<td align="center">ATCC 49247</td>
<td align="center">27 - 33</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">ATCC 25923</td>
<td align="center">19 - 26</td>
</tr>
</tbody>
</table>
<p><span class="Underline">Note</span>:</p>
<p>Diffusion techniques are not recommended for determining susceptibility of<span class="Italics"> Streptococcus pneumoniae </span>to trimethoprim.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">4</a></dt>
<dd>Blood-containing media (except for lysed horse blood) are generally not suitable for testing trimethoprim. Mueller-Hinton agar should be checked for excessive levels of thymidine. To determine whether Mueller-Hinton medium has sufficiently low levels of thymidine and thymine, an<span class="Italics"> Enterococcus faecalis </span>(ATCC 29212 or ATCC 33186) may be tested with trimethoprim/sulfamethoxazole disks. A zone of inhibition ≥20 mm that is essentially free of fine colonies indicates a sufficiently low level of thymidine and thymine.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">5</a></dt>
<dd>Interpretative criteria applicable only to tests performed by disk diffusion method using<span class="Italics"> Haemophilus </span>Test Medium (HTM).<span class="Sup">2</span>
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PRIMSOL Solution is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the conditions listed below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Pediatric Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h3>
<p class="First">For the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> Streptococcus pneumoniae </span>and<span class="Italics"> Haemophilus influenzae.</span></p>
<p><span class="Bold">NOTE: </span><span class="Italics">Moraxella catarrhalis </span>isolates were found consistently resistant to trimethoprim<span class="Italics"> in vitro. </span>Therefore, when <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with<span class="Italics"> Moraxella catarrhalis </span>is suspected, the use of alternative antimicrobial agents should be considered. PRIMSOL is not indicated for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or prolonged administration in <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> at any age.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h3>
<p class="First">For the treatment of initial episodes of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:<span class="Italics"> Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter </span>species and coagulase-negative<span class="Italics"> Staphylococcus </span>species, including<span class="Italics"> S. saprophyticus</span>.</p>
<p>Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The results of one multicenter, 30-day, comparative, randomized clinical trial without tympanocentesis in 262 pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> (AOM) are shown below. In this clinical trial, strict evaluability criteria were used to determine clinical response.</p>
<table width="75%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">PRIMSOL</th>
<th class="Rrule" align="center">SMX + TMP<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>sulfamethoxazole + trimethoprim oral suspension</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Enrolled</td>
<td class="Rrule" align="center">133</td>
<td class="Rrule" align="center">129</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Evaluable</td>
<td class="Rrule" align="center">130</td>
<td class="Rrule" align="center">129</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinical Cure</td>
<td class="Rrule" align="center">64/130 (49%)</td>
<td class="Rrule" align="center">63/129 (49%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinical Improvement</td>
<td class="Rrule" align="center">30/130 (23%)</td>
<td class="Rrule" align="center">31/129 (24%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Relapse/Recurrence</td>
<td class="Rrule" align="center">19/130 (15%)</td>
<td class="Rrule" align="center">18/129 (14%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Outcome (based on 95% confidence interval)</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">PRIMSOL equivalent to TMP + SMX</td>
</tr>
</tbody>
</table>
<p>The results of an uncontrolled 30-day trial with tympanocentesis in 120 pediatric patients with AOM are shown below:</p>
<table width="75%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Number of patients</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Enrolled</td>
<td class="Rrule" align="center" colspan="2">120</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinically Evaluable</td>
<td class="Rrule" align="center" colspan="2">102</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Microbiologically Evaluable</td>
<td class="Rrule" align="center" colspan="2">58</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinical Cure</td>
<td class="Rrule" align="center" colspan="2">50/102 (49%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinical Improvement</td>
<td class="Rrule" align="center" colspan="2">22/102 (22%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clinical Relapse/Recurrence</td>
<td class="Rrule" align="center" colspan="2">20/102 (20%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Microbiologic Eradication Rates n=58</td>
<td class="Rrule" align="center">Day 5 post-therapy</td>
<td class="Rrule" align="center">Day 20 post-therapy</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center">16/20 (80%)</td>
<td class="Rrule" align="center">14/20 (70%)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center">14/17 (82%)</td>
<td class="Rrule" align="center">13/17 (77%)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Moraxella catarrhalis, </span>isolated from five patients, was found consistently resistant to trimethoprim<span class="Italics"> in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PRIMSOL is contraindicated in individuals hypersensitive to trimethoprim and in those with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Experience with trimethoprim alone is limited, but it has been reported rarely to interfere with hematopoiesis, especially when administered in large doses and/or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>.</p>
<p>The presence of clinical signs such as <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> or <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> may be early indications of serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Trimethoprim should be given with caution to patients with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Folates may be administered concomitantly without interfering with the antibacterial action of trimethoprim. Trimethoprim should also be given with caution to patients with impaired renal or hepatic function. If any clinical signs of a <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorder</span> are noted in a patient receiving trimethoprim, a complete blood count should be obtained and the drug discontinued if a significant reduction in the count of any formed blood element is found.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">PRIMSOL may inhibit the hepatic metabolism of phenytoin. Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Trimethoprim can interfere with a serum methotrexate assay as determined by the competitive binding protein technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).</p>
<p>The presence of trimethoprim may also interfere with the Jaffé alkaline picrate reaction assay for creatinine resulting in overestimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been conducted with trimethoprim. Trimethoprim was demonstrated to be non-mutagenic in the Ames assay. No chromosomal damage was observed in human leukocytes cultured<span class="Italics"> in vitro </span>with trimethoprim; the concentration used exceeded blood levels following therapy with PRIMSOL. No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Trimethoprim has been shown to be teratogenic in the rat when given in doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses 6 times the human therapeutic dose.</p>
<p>While there are no large well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell,<span class="Sup">3</span> in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim plus sulfamethoxazole.</p>
<p>There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received trimethoprim plus sulfamethoxazole at the time of conception or shortly thereafter.</p>
<p>Because trimethoprim may interfere with folic acid metabolism, PRIMSOL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.5.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Trimethoprim is excreted in human milk. Because trimethoprim may interfere with folic acid metabolism, caution should be exercised when PRIMSOL is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety of trimethoprim has not been established in pediatric patients below the age of 2 months. The effectiveness of trimethoprim in the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> has not been established in patients below the age of 6 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact FSC Laboratories, Inc. at 1-866-764-7822, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Adverse Events Reported During Pediatric Clinical Trials With PRIMSOL</h2>
<p class="First">The following table lists those drug-related adverse events reported most frequently during the clinical trials in pediatric patients aged 6 months to 12 years. Most of these events were determined to be mild. The incidence of drug-related adverse events was significantly lower for PRIMSOL, which was most apparent for those events related to skin/appendages as a body system.</p>
<table width="75%">
<col align="left" valign="bottom" width="33%">
<col align="center" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">Drug-related<br>Adverse Event</th>
<th class="Rrule" align="center" colspan="2">Percent of Pediatric Patients</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">PRIMSOL<br>(N=310)</th>
<th class="Rrule" align="center">SMX + TMP<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a><br>(N=197)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>sulfamethoxazole + trimethoprim oral suspension</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Body as a whole<br>  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">2.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Digestive system<br>  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Rrule" align="center">4.2<br>1.6</td>
<td class="Rrule" align="center">4.6<br>1.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Skin/Appendages<br>  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">6.1</td>
</tr>
</tbody>
</table>
<p>An increase in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and eosinophils was noted in some pediatric patients following treatment with PRIMSOL or sulfamethoxazole + trimethoprim oral suspension.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Adverse Reactions Reported For Trimethoprim</h2>
<p class="First">In addition to the adverse events listed above which have been observed in pediatric patients receiving PRIMSOL, the following adverse reactions and altered laboratory tests have been previously reported for trimethoprim and therefore, may occur with PRIMSOL therapy:</p>
<p><span class="Italics">Dermatologic reactions: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>. At the recommended adult dosage regimens of 100 mg<span class="Italics"> b.i.d.</span>, or 200 mg<span class="Italics"> q.d.</span>, each for 10 days, the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is 2.9% to 6.7%. In clinical studies which employed high doses of trimethoprim in adults, an elevated incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was noted. These <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were maculopapular, morbilliform, pruritic and generally mild to moderate, appearing 7 to 14 days after the initiation of therapy.</p>
<p><span class="Italics">Gastrointestinal reactions: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
<p><span class="Italics">Hematologic reactions: </span><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
<p><span class="Italics">Metabolic reactions: </span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Italics">Miscellaneous reactions: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, elevation of serum transaminase and bilirubin, and increases in BUN and serum creatinine levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Acute</h2>
<p class="First">Signs of acute overdosage with trimethoprim may appear following ingestion of 1 gram or more of the drug and include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (see<a href="#chronic"> OVERDOSAGE-Chronic</a>).</p>
<p>Treatment consists of gastric lavage and general supportive measures. Acidification of the urine will increase renal elimination of trimethoprim. Peritoneal dialysis is not effective and hemodialysis only moderately effective in eliminating the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="chronic"></a><a name="section-9.2"></a><p></p>
<h2>Chronic</h2>
<p class="First">Use of trimethoprim at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, trimethoprim should be discontinued and the patient should be given leucovorin, 3 to 6 mg intramuscularly daily for three days, or as required to restore normal hematopoiesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> in Pediatric Patients</h2>
<p class="First">The recommended dose for pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 10 mg/kg trimethoprim per 24 hours, given in divided doses every 12 hours for 10 days. The following table is a guideline for the attainment of this dosage:</p>
<table width="75%">
<caption><span>Pediatric patients 6 months of age or older</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2">Weight</th>
<th class="Rrule" align="center" colspan="2">Dose (every 12 hours)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">lb</th>
<th class="Rrule" align="center">kg</th>
<th class="Rrule" align="center">tsp</th>
<th class="Rrule" align="center">mL</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">11</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">½</td>
<td class="Rrule" align="center">2.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">22</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">33</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">1½</td>
<td class="Rrule" align="center">7.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">44</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">55</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">2½</td>
<td class="Rrule" align="center">12.5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">66</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">77</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">3½</td>
<td class="Rrule" align="center">17.5</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥88</td>
<td class="Rrule" align="center">≥40</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">20</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">The usual oral adult dosage is 100 mg (10 mL) every 12 hours or 200 mg (20 mL) every 24 hours, each for 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The use of trimethoprim in patients with a creatinine clearance of less than 15 mL/min is not recommended. Patients with a creatinine clearance of 15 to 30 mL/min should receive half the dose recommended for patients of the same age with normal renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PRIMSOL (trimethoprim hydrochloride oral solution) is a dye-free, alcohol-free, bubble gum flavored, oral solution containing trimethoprim hydrochloride equivalent to 50 mg of trimethoprim in each 5 mL.<br>NDC 13551-501-01: 20 mL (3/4 ounce)<br>NDC 13551-501-05: 473 mL (1 Pint)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store between 15-25°C (59-77°F). Dispense in tight, light-resistant glass or PET plastic containers as defined in USP. Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - -Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December, 1993.</dd>
<dt>2</dt>
<dd>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December, 1993.</dd>
<dt>3</dt>
<dd>Brumfitt W, Pursell R: Trimethoprim/Sulfamethoxazole in the Treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">Bacteriuria</span> in Women,<span class="Italics"> J Infect Dis </span>128 (suppl): S657-S663, 1973.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">071714001 Revised April 2013</p>
<p>Manufactured for:<br><span class="Bold">FSC Laboratories, Inc.</span>, Charlotte, NC 28210 USA<br>www.fsclabs.com</p>
<p>Manufactured by:<br>Halo Pharmaceutical Inc., Whippany, NJ 07981 USA</p>
<p>U. S. Patent No. 5,698,562</p>
<p><span class="Bold">FSC laboratories</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label</h1>
<p class="First"><span class="Bold">NDC 13551-501-05</span></p>
<p><span class="Bold">PRIMSOL<span class="Sup">® </span></span>solution<br>trimethoprim hydrochloride<br>oral solution</p>
<p><span class="Bold">50 mg/5 mL</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">473 mL (1 pint)</span></p>
<p><span class="Bold">FSC laboratories</span></p>
<div class="Figure"><img alt="Principal Display Panel- 473 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a06ea7d8-a884-4b62-a87f-c36d824f2aa4&amp;name=primsol-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMSOL 		
					</strong><br><span class="contentTableReg">trimethoprim hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13551-501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIMETHOPRIM HYDROCHLORIDE</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">50 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FRUCTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>AMMONIUM GLYCYRRHIZATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BUBBLE GUM</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13551-501-05</td>
<td class="formItem">473 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:13551-501-01</td>
<td class="formItem">20 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA074973</td>
<td class="formItem">01/24/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>FSC Laboratories, Inc
							(169886244)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0cc7d685-5819-4103-b667-375e23299dd8</div>
<div>Set id: a06ea7d8-a884-4b62-a87f-c36d824f2aa4</div>
<div>Version: 3</div>
<div>Effective Time: 20140925</div>
</div>
</div> <div class="DistributorName">FSC Laboratories, Inc</div></p>
</body></html>
